
    
      This was designed as a single-center, single group clinical trial, and subjects include
      patients with pathologically-confirmed Gemcitabine refractory advanced pancreatic cancer.

      If subjects agree to participate in the clinical trial by signing a written consent, only
      appropriate subjects, who meet the criteria on the examinations and tests, will undergo this
      clinical trial. To participate in the clinical trial, subject's blood of more than 60 ml
      should be withdrawn to make a study drug at least 2 weeks before administration. Subjects
      should visit to hospital according to the protocol and receive a study drug. Therapeutic
      response rate, overall survival rate, time to progression and the quality of life should be
      investigated.
    
  